Creation of a Biological Collection for Medical Research Purposes for Patients at the Reference Center for Rare Diseases of the Blood Vessels of the Brain and Eye at Lariboisière Hospital

NCT07264972 | Active Not Recruiting

• 1 other identifier: APHP200773
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of establishing a biological collection associated with the existing rare cerebral vascular disease cohort is to identify new prognostic or disease progression biomarkers that could improve patient care or identify new therapeutic targets.

Conditions

Cerebrovascular Disease

Keywords

rare cerebrovascular disease

Outcome Measures

Primary Outcomes (1)

• Time required for sample storage (freezing) to ensure the stability of most measurable elements in a biological sample

  for each sample

  Up to 2 years after inclusion

Study Arms (1)

Patients with rare cerebrovascular disease

Other: additional samples for research purposes

Interventions

additional samples for research purposes OTHER

Blood and urine sampling

Patients with rare cerebrovascular disease

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with rare cerebrovascular diseases

You may qualify if:

• Confirmed diagnosis of a rare cerebral vascular disease of the brain, including:
• Familial intracranial aneurysms, cerebral amyloid angiopathy, CADASIL, familial cerebral cavernoma, familial cervical or intracranial artery dissection, vascular leukoencephalopathy (hereditary), familial hemiplegic migraine, cerebral arteriovenous malformation, moya-moya, cerebral venous thrombosis, hereditary retinal tortuosity, cerebro-retinal vasculopathies, other known rare diseases, or other rare diseases that are undetermined or not yet described.
• Participation in the MVCR cohort
• Adults \>18 years old
• Affiliation with French social security or beneficiary - Signature of informed consent

You may not qualify if:

• Incompatibility with long-term follow-up at CERVCO
• Patient under guardianship/conservatorship
• Pregnant or breastfeeding women
• Patient under AME

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

Study Sites (1)

Lariboisière hospital

Paris, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood Urine

MeSH Terms

Conditions

Cerebrovascular Disorders

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 24, 2025
• First Posted: December 4, 2025
• Study Start: January 21, 2021
• Primary Completion (Estimated): July 31, 2027
• Study Completion (Estimated): July 31, 2027
• Last Updated: December 4, 2025

Record last verified: 2025-11

Locations

FR (1)